From: Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
Subtype
Samples
CK5/6+ (%)
EGFR+ (%)
CK/EGFR+ (%)*
KRASmut (%)
TN
35
17 (48.6)
25 (71.4)
15 (42.8)
0 (0.0)
BS
27
17 (63.0)
25 (92.6)
15 (55.5)